A5007321564- Monoclonal and Polyclonal Antibodies Research
- Immunotherapy and Immune Responses
- T-cell and B-cell Immunology
- Glycosylation and Glycoproteins Research
- Colorectal Cancer Screening and Detection
- Immune Cell Function and Interaction
- Autoimmune Neurological Disorders and Treatments
- Lung Cancer Research Studies
- Blood groups and transfusion
- Immunodeficiency and Autoimmune Disorders
- Research on Leishmaniasis Studies
- Cancer Immunotherapy and Biomarkers
- Ovarian function and disorders
- Neuroendocrine Tumor Research Advances
- Myasthenia Gravis and Thymoma
- Lung Cancer Diagnosis and Treatment
- Endometrial and Cervical Cancer Treatments
- Diabetes and associated disorders
- Trypanosoma species research and implications
- Asthma and respiratory diseases
- Hepatocellular Carcinoma Treatment and Prognosis
- RNA Interference and Gene Delivery
- Toxin Mechanisms and Immunotoxins
- Gastric Cancer Management and Outcomes
- Diverticular Disease and Complications
Pfizer (United Kingdom)
2023-2025
Nottingham University Hospitals NHS Trust
2012-2024
Hampshire Constabulary
2024
University of Nottingham
2013-2023
Bowel Cancer UK
2018-2023
Queen's Medical Centre
2010-2021
Oxford Centre for Diabetes, Endocrinology and Metabolism
2018
University of Oxford
2012-2018
Nottingham City Hospital
2007-2017
Royal Derby Hospital
2015
People with lung cancer usually present at a late stage in the course of their disease when chances long-term survival are low. At there is little to offer for early diagnosis, even those high risk developing disease. Autoantibodies have been shown be circulation people various forms solid tumour before cancer-associated antigens can detected, and these molecules measured up 5 years symptomatic disease.To assess potential panel tumour-associated autoantibody profiles as an aid other...
BackgroundAutoantibodies may be present in a variety of underlying cancers several years before tumours can detected and testing for their presence allow earlier diagnosis. We report the clinical validation an autoantibody panel newly diagnosed patients with lung cancer (LC).Patients methodsThree cohorts LC were identified: group 1 (n = 145), 2 241) 3 269). Patients individually matched by gender, age smoking history to control individual no malignant disease. Serum samples obtained after...
ABSTRACT Mycograb ( Neu Tec Pharma plc) is a human genetically recombinant antibody against fungal heat shock protein 90 (HSP90). Antibody to HSP90 closely associated with recovery in patients invasive candidiasis who are receiving amphotericin B (AMB). Using vitro assays developed for efficacy assessment of chemotherapeutic antifungal drugs, showed activity wide range yeast species (MICs Candida albicans [fluconazole {FLC}-sensitive and FLC-resistant strains], krusei , tropicalis glabrata...
Aberrant glycosylation on glycoproteins that are either presented the surface or secreted by cancer cells is a potential source of disease biomarkers and provides insights into pathogenesis. N-Glycans total serum from advanced breast patients healthy individuals were sequenced HPLC with fluorescence detection coupled exoglycosidase digestions mass spectrometry. We observed significant increase in trisialylated triantennary glycan containing α1,3-linked fucose which forms part sialyl Lewis x...
Tumor-associated autoantibodies (AAbs) have been described in patients with lung cancer, and the EarlyCDT®-Lung test that measures such AAbs is available as an aid for early detection of cancer high-risk populations. Improvements specificity would improve its cost-effectiveness, well reduce anxiety associated false positive tests. Samples from 235 newly diagnosed matched controls were measured presence to a panel six (p53, NY-ESO-1, CAGE, GBU4-5, Annexin I, SOX2) or seven SOX2, HuD, MAGE A4)...
Abstract Recent publications have reported the technical and clinical validation of EarlyCDT-Lung, an autoantibody test which detected elevated autoantibodies in 40% lung cancers at diagnosis. This manuscript reports results EarlyCDT-Lung run on four new (postvalidation) data sets. The following cohorts patients (n = 574) with newly diagnosed cancer were identified: group 1 122), 100% small cell (SCLC); 2 249), 97% non-small (NSCLC); 3 NSCLC; 4 81), 62% NSCLC. Serum samples obtained after...
To determine the frequency and range of paraneoplastic neurologic disorders (PNDs) neuronal antibodies in small cell lung carcinoma (SCLC).Two hundred sixty-four consecutive patients with biopsy-proven SCLC were recruited at time tumor diagnosis. All underwent full examination. Serum samples taken prior to chemotherapy analyzed for 15 antibodies. Thirty-eight healthy controls parallel.PNDs quite prevalent (n = 24, 9.4%), most frequently Lambert-Eaton myasthenic syndrome (3.8%), sensory...
Glucagon is the body's main hyperglycemic hormone, and its secretion dysregulated in type 2 diabetes mellitus (T2DM). The incretin hormone glucagon-like peptide-1 (GLP-1) released from gut used T2DM therapy. Uniquely, it both stimulates insulin inhibits glucagon thereby lowers plasma glucose levels. In this study, we have investigated action of GLP-1 on release human pancreatic islets. Immunocytochemistry revealed that only <0.5% α-cells possess detectable GLP-1R immunoreactivity. Despite...
MUC1 is a high molecular weight glycoprotein that overexpressed in breast cancer. Aberrant O-linked glycosylation of cancer has been implicated disease progression. We investigated the purified from serum an advanced patient. O-Glycans were released by hydrazinolysis and analyzed liquid chromatography-electrospray ionization-mass spectrometry performance chromatography coupled with sequential exoglycosidase digestions. Core 1 type glycans (83%) dominated profile which also confirmed levels...
We investigated the presence of autoantibodies as immunobiomarkers to a panel tumor-associated antigens in group individuals with small cell lung cancer (SCLC), disease that has poor overall prognosis and therefore may benefit most from early diagnosis.Sera 243 patients confirmed SCLC normal controls matched for age, sex, smoking history were analyzed these (i.e., p53, CAGE, NY-ESO-1, GBU4-5, Annexin I, SOX2, Hu-D) by ELISA.Autoantibodies seen at least 1 6 55% all patients' sera tested,...
New national guidance on urgent referral for investigation of colorectal cancer included faecal occult blood testing in 2015. A service evaluation immunochemical (FIT) and anaemia as risk stratification tools symptomatic patients suspected having CRC was undertaken. Postal FIT incorporated into the 2-week wait (2WW) pathway all without rectal bleeding 2016. Patients were investigated 2WW normal, outcomes investigations recorded prospectively. Anaemia defined a haemoglobin level below 120 g/l...
Cathepsin D is a proteolytic enzyme that normally localized in the lysosomes and involved malignant progression of breast cancer. There are conflicting results regarding significance as prognostic predictor marker This study aimed to evaluate expression early-stage
Breast tissue expression of the ERBB proto-oncogene family has been extensively studied. It was recently shown that epidermal growth factor receptor (EGFR; c-erbB-1) and (HER)2 (c-erbB-2) can be detected in serum breast cancer patients. The clinical relevance this not fully established.EGFR HER2 immunoassays were conducted blood from 57 patients whom paired samples available (from times primary metastatic diagnoses), 96 49 normal individuals. Of with samples, for eight.Serum levels EGFR...
Aims Tumour‐infiltrating lymphocytes ( TIL s) are an important component of the immune response to cancer and have a prognostic value in breast cancer. Although several studies investigated role T cancer, B ‐Bs) ductal carcinoma situ DCIS ) remains uncertain. This study aimed assess ‐Bs . Methods results Eighty cases (36 pure 44 mixed with invasive cancer) were stained immunohistochemically for lineage markers CD 19, 20 plasma cell marker 138. density localization assessed, including...
We introduced primary care access to faecal immunochemical testing (FIT) as a stratification tool for symptomatic patients considered be at risk of colorectal cancer (CRC) prior urgent referral. aimed evaluate clinical and pathway outcomes during the first 6 months this novel approach.FIT was recommended all who consulted their general practitioner with lower gastrointestinal symptoms other than rectal bleeding mass. undertook retrospective audit results FIT, related resource utilization on...